Boardroom Alpha
Start trial
10-Q primary document
OKUR · Quarterly Report (Form 10-Q) · Filed May 5, 2026

Onkure Therapeutics Inc — 10-Q exhibit

okur-ex32_1.htm
Onkure Therapeutics Inc on Boardroom Alpha
EX-32.1

Exhibit 32.1

 

Statement Pursuant to 18 U.S.C. Section 1350,

As required by Section 906 of the Sarbanes-Oxley Act of 2002

 

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Nicholas A. Saccomano, President and Chief Executive Officer of OnKure Therapeutics, Inc. (the “Company”), and Jason Leverone, Chief Financial Officer of the Company, each hereby certifies that, to the best of his or her knowledge:

(1)
The Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026, to which this Certification is attached as Exhibit 32.1 (the “Quarterly Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and
(2)
The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: May 5, 2026

By:

/s/ Nicholas A. Saccomano, Ph.D.

 

Name:

Nicholas A. Saccomano, Ph.D.

 

Title:

President and Chief Executive Officer

 

 

(Principal Executive Officer)

 

 

Date: May 5, 2026

By:

/s/ Jason Leverone

 

Name:

Jason Leverone

 

Title:

Chief Financial Officer

 

 

(Principal Financial and Accounting Officer)

 

 

This certification accompanies the Quarterly Report to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Quarterly Report), irrespective of any general incorporation language contained in such filing.

 

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer